Author Archives: Hima

Antigen Spreading and Immune-Based Therapies: An Interview with the National Cancer Institute’s James L. Gulley

Let’s start with the basic question: how are immunotherapies different from other classes of anti-cancer agents? James L. Gulley, MD, PhD: To understand why immunotherapeutic agents might produce different outcomes than those expected for other modalities, we need to first lay a foundation for understanding how exactly these agents are different. It’s important to note that therapeutic vaccines, unlike conventional ... Read More »

The Changing Landscape of Prostate Cancer

Prostate cancer is the most common non-cutaneous malignancy in men, accounting for more than 28,000 deaths in the United States every year; however, how to prevent, diagnosis, and treat prostate cancer remains one of the most debatable topics in oncology today. Read More »

Molecular Pathogenesis and Progression of Prostate Cancer

Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous malignancy and second leading cause of cancer-related deaths in US males. Clinically, locally confined disease is treated surgically and/or with radiation therapy. Read More »

Molecular Diagnosis of Prostate Cancer: Are We Up to Age?

Prostate cancer (PCa), a highly heterogeneous disease, is the one of the leading cause of morbidity and mortality in the developed countries. Historically used biomarkers such as prostatic acid phosphatase (PAP), serum prostate-specific antigen (PSA), and its precursor have not stood the challenge of sensitivity and specificity. Read More »

MCRPC Featured Article 1

Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials   Read More »

Introduction to the IMPACT Trial

Lower Baseline prostate-specific antigen is associated with a greater overall survival benefit from Sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (Impact Trial)   Read More »